aaiPharma Inc announced the launch of the 75 mg and 100 mg Azasan (azathioprine tablets) products into the marketplace. These proprietary new dosage forms are now commercially available, and promotion is underway.

In addition, the Company reported that IMS prescription data for the 50 mg dosage form of Azasan is trending very positively. Since the July 2002 launch of aaiPharma's 50 mg product, aaiPharma's share of total azathioprine prescriptions has increased from 2% in August 2002, the month after the Company launched the product, to 31.5% as of March 14, 2003.

"Our market share for the Azasan 50 mg product is trending nicely," according to David Hurley, President of the Pharmaceuticals Division of aaiPharma. "This trend, coupled with the launch of our proprietary Azasan dosage strengths, demonstrates our ability to innovate established products through science, and execute on our sales and marketing strategy."

The Company indicated that its field organization, which now numbers more than 80 representatives, was trained last month at the Company's National Sales Meeting, and began detailing the new Azasan products this week.

Previously unavailable, these new 75 mg and 100 mg Azasan tablet strengths will provide physicians with more flexible dosage options and contribute to enhanced patient compliance. With this launch and the Company's currently marketed 50 mg dosage form, aaiPharma now offers the most comprehensive line of azathioprine dosage forms on the market today.